New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
09:29 EDTHTBXHeat Biologics ends relationship with Chief Medical Officer
Heat Biologics disclosed in a regulatory filing that the company severed its relationship with Dr. Sandra Silberman, its Chief Medical Officer. Melissa Price, Ph.D., the company’s current Vice President of Clinical and Regulatory Affairs, will assume the lead of all of the company’s clinical and regulatory development with the aid of the company’s newly formed Clinical Advisory Board, the company said.
News For HTBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
13:47 EDTHTBXHeat Biologics focus on combo trial a positive, says Cantor
After Heat Biologics (HTBX) announced plans for a Phase 1b trial investigating the combination of its HS-110 vaccine and Bristol-Myers' (BMY) PD-1 inhibitor nivolumab in non-small cell lung cancer and said it is winding down its ongoing Phase 2 trial with HS-110 that does not include a checkpoint inhibitor combination, Cantor Fitzgerald analyst Mara Goldstein called the decision a positive. The new course preserves the current timeline and cash while making the clinical program more relevant to the evolving standard of care, according to Goldstein, who keeps a Buy rating and $18 price target on Heat Biologics shares.
07:16 EDTHTBXHeat Biologics to host conference call
Conference call to discuss clinical trial combining HS-110 and PD-1 checkpoint inhibitor in NSCLC will be held on September 1 at 8:30 am. Webcast Link
07:07 EDTHTBXHeat Biologics announces clinical trial combining HS-110, PD-1 in NSCLC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use